Dragonfly Therapeutics, Inc. announced an expansion of its strategic collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to discover, develop and commercialize a number of Dragonfly’s candidate natural killer (“NK”) cell engager immunotherapies for oncology, infectious disease and immune disorders.